Chieh‐Hsiang Lu

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial

Chieh‐Hsiang Lu, Kyung Wan Min, Lee‐Ming Chuang et al. · Journal of Diabetes Investigation · 2015 · 66 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells

Chieh‐Hsiang Lu, Shu‐Hsin Chen, Yi-Sheng Chang et al. · Pharmacological Research · 2016 · 60 citations

Life Sciences, Oncology, Pharmacology +16

Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells

Fang-Ping Kung, Yun-Ping Lim, Wen-Ying Chao et al. · Cancers · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17